Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@MrJursdictional pointed out something incredible about $gncp ! Their new lithium venture has the maxwell family on the board. @MaxwellBldrsInc owner Dave Maxwell and his wife, pres of MB, Lonia are pres and director of USA Lithium. ?? https://maxwellbuilders.net/?page_id=475
@MrJursdictional pointed out something incredible about $gncp ! Their new lithium venture has the maxwell family on the board. @MaxwellBldrsInc owner Dave Maxwell and his wife, pres of MB, Lonia are pres and director of USA Lithium. 👀 https://t.co/HvNojzlvgT https://t.co/h9SP0QBhlo pic.twitter.com/NMrTz6bsIL
— 🄶🄾🄰🅃🅂🄼🄾🄽🄴🅈 📉📈 (@goatsmoney) February 25, 2022
Love to all in Jesus!!! Happy and joy filled days NO MATTA WHAT!!!! :) :) :)
Love to all in Jesus!!! Happy and joy filled days NO MATTA WHAT!!!! :) :) :)
Love to all in Jesus!!! Happy and joy filled days NO MATTA WHAT!!!! :) :) :)
SEC Proposes Short Sale Disclosure Rule, Order Marking Requirement, and CAT Amendments
Agency Also Reopens Comment Period for Proposed Rule 10c-1
FOR IMMEDIATE RELEASE
2022-32
Washington D.C., Feb. 25, 2022 —
The Securities and Exchange Commission today announced that it has voted to propose changes that would provide greater transparency to investors and regulators by increasing the public availability of short sale related data. New Exchange Act Rule 13f-2 and the corresponding Form SHO would require certain institutional investment managers to report short sale related information to the Commission on a monthly basis. The Commission then would make aggregate data about large short positions, including daily short sale activity data, available to the public for each individual security.
“Proposed Rule 13f-2 would make aggregate data about large short positions available to the public for individual equity securities,” said SEC Chair Gary Gensler. “This would provide the public and market participants with more visibility into the behavior of large short sellers. The raw data reported to the Commission on a new Form SHO would help us to better oversee the markets and understand the role short selling may play in market events. It’s important for the public and the Commission to know more about this important market, especially in times of stress or volatility.”
Specifically, Rule 13f-2 would require institutional investment managers exercising investment discretion over short positions meeting specified thresholds to report on the Proposed Form SHO information relating to end-of-the-month short positions and certain daily activity affecting such short positions. The Commission would aggregate the resulting data by security, thereby maintaining the confidentiality of the reporting managers, and publicly disseminated the data to all investors. This new data would supplement the short sale data that is currently publicly available from FINRA and stock exchanges.
The Commission also voted to propose a new provision of Regulation SHO, Rule 205, which would establish a new “buy to cover” order marking requirement for broker-dealers. Regulation SHO, which is the Commission’s primary short selling regulation, requires broker-dealers to identify each sale order that it effects as either “long,” “short,” or “short-exempt,” but it does not currently have a corresponding requirement for purchase orders. Proposed Rule 205 would require a broker-dealer to mark a purchase order as “buy to cover” if the purchaser has any short position in the same security at the time the purchase order is entered. This information will be especially useful to the Commission in reconstructing significant market events and identifying potentially abusive trading practices including short squeezes.
Relatedly, the Commission voted to amend the national market system plan governing the consolidated audit trail (CAT). The amendment would require CAT reporting firms to report “buy to cover” information to CAT. The proposed amendments also include a provision that would require each CAT reporting firm to indicate where it is asserting use of the bona fide market making exception under Regulation SHO.
In light of Proposed Rule 13f-2, the Commission voted to reopen the comment period for Proposed Exchange Act Rule 10c-1. Rule 10c-1 was proposed by the Commission on November 18, 2021, to increase the transparency and efficiency of the securities lending market by requiring any person that loans a security on behalf of itself or another person to report the material terms of those securities lending transactions and related information to a registered national securities association. The initial Comment period for proposed Rule 10c-1 ended on January 7, 2022.
$GGII !!! :)
1,135 Followers https://twitter.com/TheRegenBio
$RGBP
1,120 Followers https://twitter.com/TheRegenBio
Regen just received patent for small molecule modulators US 11,241,427 B2
3:46 PM · Feb 23, 2022·Twitter Web App
Regen just received patent for small molecule modulators US 11,241,427 B2
— Regen BioPharma Inc. (@TheRegenBio) February 23, 2022
1,097 Followers https://twitter.com/TheRegenBio
1,083 Followers https://twitter.com/TheRegenBio
God works in mysterious ways!!! :) $DWAC !!!
1,064 Followers https://twitter.com/TheRegenBio
1,018 Followers https://twitter.com/TheRegenBio
1,010 Followers https://twitter.com/TheRegenBio
1,003 Followers https://twitter.com/TheRegenBio
965!!!! :) $RGBP
https://twitter.com/TheRegenBio
950 Followers now.... :) $RGBP
$GNCP GNCC Capital, Inc. files its Q1 Report to December 31, 2021
$GNCP GNCC Capital, Inc. (https://t.co/tllm2pvtE5) files its Q1 Report to December 31, 2021. A Link: https://t.co/kE44EAONAV
— GNCC Capital, Inc. (@gncccapital) February 20, 2022
Hi Squirrely!! :)
I love you Jesus! Thank you for saving me!!! :)
I love you Jesus! Thank you for saving me!!! :)
So what.. Moving onto better things!! :) $RGBPP !! :)
ummm... we don't know what we don't know.. :) There has been recent PR's showing movement.. $RGBP
Go where? Why would Regen and Cornell terminate and Regen to "go somewhere else?"
Exactly! $RGBP
:) lol... Gotta terminate an agreement to go somewhere else! Hello?? :) $RGBP
Nope!! Just moving in a different direction... :) $RGBP
Oncology Pharma Expands on Feasibility Studies and Data
February 17 2022 - 06:16AM
InvestorsHub NewsWire
Alert
Print
Share On Facebook
SAN FRANCISCO, CA -- February 17, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included results of formulations and data on licensed technology with NanoSmart Pharmaceuticals demonstrating the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.
The active pharmaceutical ingredient, dactinomycin is an actinomycin antibiotic belonging to a class of polypeptide antitumor antibody. It inhibits transcription by binding to DNA at the transcription initiation complex and preventing elongation of RNA chain by RNA polymerase. Dactinomycin has been used both alone and in combination with other drug products to treat a wide range of cancers. Specifically, it has demonstrated clinical benefit for the treatment of pediatric and adult sarcomas and is used routinely as part of standard treatment regimens in clinical practice for the treatment of Ewing's Sarcoma.
The benefits of lipid nanoparticle drug delivery are well understood. In addition to sequestering toxic drugs from healthy tissues, the small particle size (100 nm – 400 nm diameter range) enables passive accumulation of the drug at the tumor sites. Passive accumulation occurs because blood capillaries associated with tumors have enlarged "pores" between the lining endothelial cells and nanoparticles are able to pass through these "leaky" capillaries and enter the interstitial fluid space within the tumor mass. Additionally, conjugation to polyethylene glycol (PEG) protects the nanoparticle from being recognized and detoxified by the liver.
Oncology Pharma, Inc. has licensed and has financed the early feasibility studies to date for this technology from NanoSmart and intends on commercially developing, distributing and utilizing this product and continuing the studies so that it can jointly bring this product to market with the target of initially focusing on the pediatric market. The Company believes the pediatric market is under-served and it gives an edge to Oncology Pharma as a pioneer in this critical market and allows Oncology Pharma to be a significant participant in this well deserved market.
Described below are the results of the early studies we addressed before:
Initial Formulations
• Tested for drug incorporation (visual): > 95% drug incorporation.
• 50% remaining after 3 hours (better than free-drug formulation).
• However, formulation had aggregation after several days in 4oC storage. This is not optimal for formal development, but more favorable solutions were found with further testing.
Series A-1 Formulation
• Tested for drug incorporation (spectrophotometer – quantitative measurement) – 100% drug incorporated.
• However, formulation had aggregation after several days in 4oC storage.
Series A-2 Formulation
• Preparation showed aggregation overnight at 4oC, could not be filtered through 0.22 um membrane filter.
• Decided to switch to natural vs. hydrogenated oil to increase amount of drug incorporation and to reduce aggregation (natural oil appears to aggregate less than hydrogenated in storage).
• Series B-1 Formulation (natural oil)
• Attempted to filter through 0.22 um filter. Filter clogged quickly, indicating significant aggregation after formulation (prior to storage).
Series B-2 Formulation
• Dilution and minor change to B-1 formulation change and extrude 10X.
• Showed 100% incorporation of drug (visual).
• Still visible aggregation upon storage at 4oC (approx. 50%) – still possible to filter through a 0.22 um filter.
• Upon additional research, appears that repeated extrusion may impart additional energy to nanoemulsion causing nanodroplets to aggregate. In addition, an ice bath was not used during this prep which may be a factor.
Series B-3 Formulation
• B-2 formulation was extruded 3x through 400/200/100 nm membranes at room temperature.
• B-3 formulation was possible to filter trough 0.22 um filter without clogging (see picture next slide).
• Increasing amount of glycerol added to B-3 formulation did not improve formulation.
• Drug release study conducted at 37oC:
70% remaining after 1 hour, 35% remaining after 3 hours, 5% remaining after 6 hours. Improving upon this is desirable, but this is workable as a time-release formulation.
• Submitting split samples for physical characterization and initial analytical method validation.
The proprietary nanoemulsion being developed also has the novel potential to be stable during storage for an extended period of time. This is in contrast to most lipid nanoparticle formulations that typically have a very short shelf-life once formulated. The nanoemulsion formulation can likely be utilized for a broad range of cancer drugs that are lipophilic (i.e. not water soluble), thus expanding the potential to license additional drug formulations utilizing this same platform technology, with each novel drug being safer and more effective than the predicate drug formulation currently on the market.
Advancement continues to be made on the feasibility testing and initial gathering of data of nanoemulsion formulations for dactinomycin. Early work continues to be promising with formulations demonstrating a satisfactory level of nanoemulsion loading and retention of dactinomycin. Studies to assess the physical characterization of the formulations, as well as quantitative performance measures (e.g., storage stability, time-to-release, etc.) are underway.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
https://ih.advfn.com/stock-market/USOTC/oncology-pharma-pk-ONPH/stock-news/87320814/oncology-pharma-expands-on-feasibility-studies-and
$RGBP Also on Medelis' Linkedin page!!
https://www.linkedin.com/company/medelis-inc-/
Medelis: OncologyCRO@oncologycro $RGBP
$RGBP - Regen BioPharma to start mRNA anti-cancer vaccine development program https://t.co/Sy3ufnVJHt
— Medelis: OncologyCRO (@oncologycro) February 15, 2022
Cancer Vaccines – Promising Research Gets Closer to Reality
https://medelis.com/cancer-vaccines-promising-research-gets-closer-to-reality/
$RGBP !!! :)
$TLSS !!! :)
$GNCP !!! :)
Idiocracy "I like money"!!! :) $RGBP
Idiocracy "I like money"!!! :) $DWAC
Nice! $ONPH just seems well pregnant!!! :) Along with $RGBP !! :)
yep!! Love it and things are now starting to happen! :) $RGBP
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
By
ACCESSWIRE
Published
February 14, 2022
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. (“The Company”) (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen’s patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES (“MRNA Vaccines”).
In April of 2021 ONPH was granted an exclusive right and license for the development and commercialization of the MRNA Vaccines for the treatment in humans of pancreatic cancer.
The current intent is that IND (“Investigational New Drug Application”) enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing.
This patented technology (patent issued in Aug, 2021) is a cellular vaccine that uses a modified mRNA molecule expressing peptides of Survivin which are exposed to dendritic cells. These dendritic cells are then matured and infused into the cancer patient’s circulation where they are expected to hone in on the cancer and destroy it. There are currently several clinical trials ongoing around the world using Survivin as a vaccine for multiple different cancers which further supports this approach.
“I am very excited to get our newly patented modified mRNA technology advanced to the point whereby an IND can be submitted to the FDA,” says David Koos, CEO and Chairman of Regen. “I expect that once our experimental protocols are set up, the path to a cleared IND from the FDA will be straightforward.”
“Due to the COVID pandemic, the FDA now understands the excellent safety profile of modified mRNA technology,” says the CEO of ONPH. “We believe this technology which targets Survivin and uses the patient’s own immune system to kill their tumors will have the same success in treating pancreatic cancer that the CAR-T cell approach is having in liquid tumors.”
The initiation and completion of the abovementioned is contingent upon several factors including, but not limited to, the execution of one or more mutually acceptable definitive agreements between the parties and securing of adequate financing. Although the parties are confident that any and all contingencies can be satisfied no assurance can be given that any such agreements shall be executed or, if executed, shall not contain terms and conditions materially different from the terms and conditions currently contemplated or that adequate financing can be secured.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the ‘Company’) is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
https://www.digitaljournal.com/pr/oncology-pharma-inc-and-regen-biopharma-inc-announce-intent-to-jointly-fast-track-development-of-modified-mrna-anti-cancer-vaccine